Tech Company Financing Transactions
LyGenesis Funding Round
LyGenesis closed a $4 million financing round on 10/22/2019. Backers included Juvenescence and Longevity Fund.
Transaction Overview
Company Name
Announced On
10/22/2019
Transaction Type
Debt
Amount
$4,000,000
Round
Undisclosed
Investors
Juvenescence (Gregory Bailey)
Longevity Fund (Sergey Young)
Proceeds Purpose
This financing will enable LyGenesis's lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2730 Sidney St. 300
Pittsburgh, PA 15203
USA
Pittsburgh, PA 15203
USA
Phone
Undisclosed
Website
Email Address
Overview
LyGenesis, Inc. is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Our initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Hufford
Chief Medical Officer
Paulo Fontes
Chief Scientific Officer
Eric Lagasse
Browse more venture capital transactions:
Prev: 10/22/2019: Roostify venture capital transaction
Next: 10/22/2019: AeroCare venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs